More recently, the Canadian Diabetes Association Clinical Practice Guideline has recommended to add sodium-glucose cotransporter 2 (SGLT2) inhibitors, such as empagliflozin, in patients with type 2 diabetes with clinical cardiovascular disease [6]. The gene discussed is SLC5A2; the disease is diabetes mellitus.